Kliniken Essen-Mitte

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025 (2025) Thill M, Janni W, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, et al. Journal article, Review article AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025 (2025) Park-Simon TW, Müller V, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, et al. Journal article, Review article Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial (2025) Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al. Journal article CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism (2025) Sinn M, Lohneis A, Mohamed O, Roderburg C, Hellmann M, Südhoff T, Christoph DC, et al. Journal article [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial (2025) Pabst KM, Weber MM, Laschinsky C, Sandach P, Bartel T, Küper AT, Kessler L, et al. Journal article Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial (2024) Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, et al. Journal article Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease (2024) Ramachandran D, Tyrer JP, Kommoss S, DeFazio A, Riggan MJ, Webb PM, Fasching P, et al. Journal article Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (2024) Schmid P, Cortes J, Dent R, Mcarthur H, Pusztai L, Kümmel S, Denkert C, et al. Journal article Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] (2024) de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024) Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article